Timor-Leste
Tuberculosis profile
Population  2013 1.1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.99 (0.54–1.6) 87 (48–141)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 9.1 (4.3–16) 802 (382–1 375)
Incidence  (includes HIV+TB) 5.6 (4.6–6.7) 498 (409–596)
Incidence (HIV+TB only)        
Case detection, all forms (%) 67 (56–81)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.8–2.7) 16 (12–20)
MDR-TB cases among notified pulmonary
TB cases
72 (59–89) 11 (8–13)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 565   55
Pulmonary, clinically diagnosed 1 723   0
Extrapulmonary 414   0
       
Total new and relapse 3 757    
Previously treated, excluding relapses 11    
Total cases notified 3 768    
Among 1 815 new cases:
340 (19%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 2 (3%) 132
Laboratory-confirmed RR-/MDR-TB cases     2
Patients started on MDR-TB treatment     2
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 537 (41)
HIV-positive TB patients 7 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 7 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 7 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 89
Previously treated cases registered in 2012 90
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 2
% Funded domestically 23%
% Funded internationally 77%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-29 Data: www.who.int/tb/data